Hospital
Columbia Memorial Hospital
Columbia Memorial Hospital was paid $25.69M by Medicaid between Jan 2018 and Dec 2024, across 311 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 13% of everything it billed.
33Billing provider infoCOLUMBIA MEMORIAL HOSPITAL
HUDSON, NY 12534
HUDSON, NY 12534
33aNPI1528024718assigned 04/25/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$25.69M
24GClaims684,254
24DCodes billed311
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#54 of 231
Median peer was paid$561K
This provider vs. median46×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,030 | $629K | |
| 2019 | 46,985 | $1.85M | |
| 2020 | 115,889 | $4.29M | |
| 2021 | 138,619 | $5.34M | |
| 2022 | 136,986 | $5.03M | |
| 2023 | 138,156 | $4.99M | |
| 2024incomplete | 97,589 | $3.56M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 13% | 36,347 | 34,332 | $3.43M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 12% | 26,846 | 25,389 | $3.06M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.6% | 13,575 | 12,507 | $1.71M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.3% | 7,669 | 7,271 | $1.10M |
| G0378 | Hospital observation service, per hour | 3.9% | 2,911 | 1,558 | $1.01M |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.9% | 5,308 | 4,435 | $994K |
| 80053 | Comprehensive metabolic panel | 2.8% | 43,023 | 33,656 | $708K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 4,869 | 4,569 | $680K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.5% | 2,618 | 2,569 | $631K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.4% | 13,190 | 3,997 | $628K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 2.4% | 3,625 | 3,574 | $615K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.4% | 4,952 | 3,537 | $612K |
299 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 2,118 | $465K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.7% | 4,376 | $429K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.6% | 993 | $423K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.3% | 17,641 | $346K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 1,306 | $331K |
| 99285 | Emergency room visit (most serious) | 1.3% | 3,551 | $331K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 1.3% | 624 | $328K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 2,169 | $315K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.2% | 5,181 | $299K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.1% | 5,271 | $295K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 9,012 | $248K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,642 | $226K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 7,435 | $223K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,013 | $218K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,971 | $189K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 697 | $188K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,092 | $174K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 1,568 | $170K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,832 | $167K |
| 97162 | <1% | 1,448 | $153K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,723 | $152K |
| Q9992 | Injection, buprenorphine extended-release (sublocade), greater than 100 mg | <1% | 97 | $140K |
| 76830 | Ultrasound, transvaginal | <1% | 3,163 | $136K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,158 | $133K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,224 | $126K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 1,114 | $121K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,586 | $113K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,094 | $107K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,408 | $103K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 13,529 | $101K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 414 | $101K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 693 | $98K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,746 | $95K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 8,633 | $84K |
| 36415 | Collection of venous blood by venipuncture | <1% | 39,221 | $82K |
| 80061 | Lipid panel | <1% | 12,815 | $80K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,727 | $75K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 2,113 | $73K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,758 | $71K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,545 | $70K |
| 92551 | <1% | 5,419 | $68K | |
| 99051 | <1% | 7,608 | $68K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,747 | $66K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 648 | $65K |
| 93971 | <1% | 961 | $65K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 316 | $63K |
| 76642 | <1% | 1,463 | $60K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,113 | $57K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,982 | $57K |
| 82607 | <1% | 4,765 | $57K | |
| 76641 | <1% | 1,059 | $56K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 83 | $55K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,652 | $55K |
| 84439 | <1% | 6,550 | $54K | |
| 86618 | <1% | 4,211 | $53K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 32,596 | $52K |
| 77065 | Tomosynthesis, mammo | <1% | 605 | $52K |
| 71250 | <1% | 677 | $52K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,524 | $52K |
| 86850 | <1% | 2,007 | $50K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 399 | $48K |
| 85055 | <1% | 1,726 | $45K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,220 | $45K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,832 | $42K |
| 71271 | <1% | 671 | $41K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,456 | $41K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,038 | $38K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,063 | $37K |
| 76536 | <1% | 1,014 | $36K | |
| 76801 | <1% | 642 | $36K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 325 | $36K |
| 82746 | <1% | 3,053 | $36K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 50 | $35K |
| 99443 | <1% | 323 | $35K | |
| 87631 | <1% | 574 | $35K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,309 | $34K |
| 86901 | <1% | 2,000 | $33K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 289 | $32K |
| 83880 | <1% | 1,149 | $31K | |
| 84153 | <1% | 1,598 | $30K | |
| 86617 | <1% | 1,391 | $28K | |
| 86235 | <1% | 667 | $27K | |
| 86900 | <1% | 2,003 | $26K | |
| 90715 | <1% | 1,114 | $25K | |
| 88342 | <1% | 645 | $25K | |
| 12001 | <1% | 59 | $24K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 52 | $24K |
| 81003 | <1% | 2,052 | $23K | |
| 97161 | <1% | 326 | $22K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 418 | $22K |
| 90686 | <1% | 3,849 | $22K | |
| 83655 | <1% | 1,519 | $20K | |
| 86803 | <1% | 2,042 | $19K | |
| 86769 | <1% | 333 | $18K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,889 | $18K |
| 93970 | <1% | 53 | $18K | |
| 81025 | <1% | 5,386 | $18K | |
| 87340 | <1% | 1,844 | $17K | |
| 77066 | Tomosynthesis, mammo | <1% | 238 | $17K |
| 82728 | <1% | 1,330 | $17K | |
| 85027 | <1% | 6,920 | $17K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 80 | $17K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 98 | $16K |
| 70496 | <1% | 42 | $13K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 113 | $13K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 354 | $13K |
| 87070 | <1% | 2,100 | $13K | |
| 83540 | <1% | 2,599 | $12K | |
| 76770 | <1% | 108 | $12K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 248 | $12K |
| 83550 | <1% | 2,393 | $11K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 193 | $11K |
| 94060 | <1% | 465 | $10K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 221 | $10K |
| 85610 | <1% | 4,378 | $10K | |
| 77080 | <1% | 269 | $10K | |
| 86140 | <1% | 3,664 | $10K | |
| 84702 | <1% | 1,897 | $10K | |
| 94729 | <1% | 346 | $9K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 208 | $8K |
| 93017 | <1% | 340 | $8K | |
| 81002 | <1% | 13,254 | $8K | |
| 82570 | <1% | 1,689 | $8K | |
| 73130 | <1% | 1,152 | $8K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 66 | $8K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 477 | $8K |
| 73562 | <1% | 925 | $7K | |
| 99442 | <1% | 106 | $7K | |
| 86762 | <1% | 526 | $7K | |
| 82043 | <1% | 1,495 | $7K | |
| 76775 | <1% | 194 | $7K | |
| 86038 | <1% | 1,393 | $7K | |
| 94727 | <1% | 358 | $7K | |
| 72100 | <1% | 704 | $7K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 14 | $7K |
| 86592 | <1% | 2,668 | $7K | |
| 73030 | <1% | 795 | $6K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 47 | $6K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 24 | $6K |
| 73221 | <1% | 29 | $6K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 25 | $6K |
| 85652 | <1% | 4,044 | $6K | |
| 86431 | <1% | 1,212 | $6K | |
| 83735 | <1% | 5,917 | $6K | |
| 83001 | <1% | 325 | $6K | |
| 73630 | <1% | 1,059 | $6K | |
| 51798 | <1% | 38 | $6K | |
| 84403 | <1% | 224 | $6K | |
| 86706 | <1% | 628 | $5K | |
| 87186 | <1% | 987 | $5K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 410 | $5K |
| 84146 | <1% | 287 | $5K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,714 | $5K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 113 | $5K |
| 73610 | <1% | 914 | $5K | |
| 93880 | <1% | 53 | $4K | |
| 84550 | <1% | 1,088 | $4K | |
| 86704 | <1% | 453 | $4K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,732 | $4K |
| 87077 | <1% | 642 | $3K | |
| 84481 | <1% | 375 | $3K | |
| 83690 | <1% | 4,663 | $3K | |
| 84402 | <1% | 133 | $3K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,298 | $3K |
| 94750 | <1% | 100 | $3K | |
| 86225 | <1% | 571 | $3K | |
| 97165 | <1% | 51 | $3K | |
| 72141 | <1% | 14 | $3K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 118 | $3K |
| 86480 | <1% | 55 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 214 | $3K |
| 82784 | <1% | 211 | $3K | |
| 88304 | <1% | 122 | $3K | |
| 86708 | <1% | 324 | $3K | |
| 86709 | <1% | 321 | $3K | |
| 29125 | <1% | 12 | $3K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,007 | $2K |
| 72110 | <1% | 118 | $2K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 78 | $2K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,701 | $2K |
| 96367 | <1% | 78 | $2K | |
| 81001 | <1% | 675 | $2K | |
| 85730 | <1% | 2,691 | $2K | |
| 82248 | <1% | 434 | $2K | |
| 99441 | <1% | 47 | $2K | |
| 59025 | Fetal non-stress test | <1% | 111 | $2K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 17 | $2K |
| 82550 | <1% | 939 | $2K | |
| 86666 | <1% | 153 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 950 | $2K |
| 74018 | <1% | 240 | $2K | |
| 86376 | <1% | 95 | $2K | |
| 73110 | <1% | 361 | $1K | |
| 86003 | <1% | 13 | $1K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 39 | $1K |
| 82947 | <1% | 2,261 | $1K | |
| 85018 | <1% | 691 | $1K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 12 | $1K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,422 | $1K |
| 20611 | <1% | 17 | $1K | |
| 85378 | <1% | 1,587 | $1K | |
| 84484 | <1% | 5,732 | $1K | |
| 82150 | <1% | 393 | $1K | |
| 88313 | <1% | 233 | $1K | |
| 20553 | <1% | 26 | $980.46 | |
| 73502 | <1% | 76 | $974.85 | |
| 88307 | <1% | 12 | $899.98 | |
| 86705 | <1% | 91 | $825.97 | |
| 87040 | <1% | 1,173 | $796.53 | |
| 82553 | <1% | 422 | $780.22 | |
| 87207 | <1% | 202 | $749.39 | |
| 80076 | <1% | 97 | $719.80 | |
| 72040 | <1% | 67 | $713.98 | |
| 94760 | <1% | 3,762 | $637.54 | |
| 82950 | <1% | 113 | $579.34 | |
| 83002 | <1% | 31 | $537.80 | |
| 87522 | Neg quan hep c or qual rna | <1% | 12 | $523.54 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,499 | $504.64 |
| 83020 | <1% | 38 | $498.16 | |
| 90656 | <1% | 104 | $467.06 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 16 | $431.06 |
| 86753 | <1% | 24 | $429.29 | |
| 82105 | <1% | 64 | $418.60 | |
| 84703 | <1% | 3,089 | $416.65 | |
| 0012A | <1% | 14 | $391.23 | |
| 80320 | <1% | 2,803 | $348.17 | |
| 86255 | <1% | 65 | $347.97 | |
| 83605 | <1% | 1,695 | $340.75 | |
| 82670 | <1% | 12 | $332.89 | |
| 82977 | <1% | 77 | $309.91 | |
| 84100 | <1% | 317 | $306.91 | |
| 87468 | <1% | 13 | $305.83 | |
| 90670 | <1% | 126 | $298.69 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 15 | $249.30 |
| 87484 | <1% | 12 | $244.72 | |
| 87469 | <1% | 12 | $244.72 | |
| 80329 | <1% | 1,749 | $240.58 | |
| 87205 | <1% | 151 | $234.72 | |
| 0011A | <1% | 13 | $201.72 | |
| 85014 | <1% | 102 | $179.04 | |
| 96127 | <1% | 13 | $178.20 | |
| 96376 | <1% | 612 | $165.89 | |
| 80335 | <1% | 1,844 | $161.30 | |
| 87427 | <1% | 12 | $133.94 | |
| 87177 | <1% | 13 | $108.60 | |
| 83615 | <1% | 137 | $107.53 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 12 | $94.16 |
| 70498 | <1% | 39 | $92.35 | |
| 87045 | <1% | 13 | $91.09 | |
| 83721 | <1% | 14 | $90.54 | |
| 93242 | <1% | 14 | $90.34 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 613 | $76.94 |
| 90723 | <1% | 30 | $75.30 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,022 | $62.48 |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 745 | $59.28 |
| 90461 | <1% | 1,905 | $50.00 | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,764 | $46.04 |
| G0008 | Administration of influenza virus vaccine | <1% | 79 | $43.05 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 996 | $38.71 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,558 | $37.66 |
| 87176 | <1% | 183 | $37.47 | |
| 82962 | <1% | 559 | $34.77 | |
| 87046 | <1% | 13 | $32.99 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,852 | $28.11 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,260 | $26.08 |
| 86308 | <1% | 12 | $24.01 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,396 | $22.90 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,444 | $22.77 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 49 | $20.86 |
| 85007 | <1% | 19 | $17.61 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,490 | $17.24 |
| 87147 | <1% | 56 | $15.84 | |
| 90662 | <1% | 13 | $14.04 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 271 | $11.98 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 102 | $7.50 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,136 | $6.86 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 416 | $6.36 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,327 | $4.49 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 305 | $3.25 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 303 | $2.08 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 20 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 72 | $0.00 |
| 90680 | 0% | 13 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 16 | $0.00 |
| 99000 | 0% | 25 | $0.00 | |
| J7609 | Albuterol, inhalation solution, compounded product, administered through dme, unit dose, 1 mg | 0% | 35 | $0.00 |
| 90677 | 0% | 39 | $0.00 | |
| 90647 | 0% | 25 | $0.00 | |
| 81374 | 0% | 12 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 12 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 13 | $0.00 |
| 90734 | 0% | 39 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 60 | $0.00 |
| 90633 | 0% | 12 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 13 | $0.00 |
| 82948 | 0% | 13 | $0.00 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 20 | $0.00 |
| 99173 | 0% | 13 | $0.00 | |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMAHONEY, BRYAN (CFO)
| Provider | Location | Paid |
|---|---|---|
| Columbia Memorial Regional Medical PLLC | Hudson, NY | $1.25M |
| Columbia Memorial Regional Medical PLLC | Catskill, NY | $18K |
| Columbia Memorial Hospital | Hudson, NY | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.